Korro announces first cohort dosed in Phase 1/2 clinical trial for KRRO-121

KRRO•2026-10-05

Korro Bio announced that the first cohort has been dosed in its Phase 1/2 ANCHOR clinical trial for KRRO-121. Dosing in UCD patients is expected to start in the first half of 2027, with an interim readout expected in the second half of 2027.

1. Trial dosing begins

Korro Bio announced that the first cohort has been dosed in the Phase 1/2 ANCHOR clinical trial for KRRO-121. The company expects dosing in UCD patients to start in the first half of 2027 and an interim readout in the second half of 2027.

Korro announces first cohort dosed in Phase 1/2 clinical trial for KRRO-121

1. Trial dosing begins

Related News

Standard BioTools agrees to sell microfluidics business to Archimed

Cattle futures hold within recent trading range but end lower on technical selling

Reliance Global Group sells Altruis Benefit Consulting for $8 million, plus up to $1 million earnout

Control Empresarial de Capitales sells 100,000 PBF Energy common shares for $8,200,000

Carvana CFO Mark W. Jenkins disposes of $4.07 million in common shares